| The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ... Hepatology 66 (5), 1444-1453, 2017 | 308 | 2017 |
| Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients B Testoni, F Lebossé, C Scholtes, F Berby, C Miaglia, M Subic, A Loglio, ... Journal of hepatology 70 (4), 615-625, 2019 | 263 | 2019 |
| Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population GV Papatheodoridis, V Sypsa, G Dalekos, C Yurdaydin, F van Boemmel, ... Journal of hepatology 68 (6), 1129-1136, 2018 | 111 | 2018 |
| The long-term benefits of nucleos (t) ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study P Lampertico, F Invernizzi, M Viganò, A Loglio, G Mangia, F Facchetti, ... Journal of hepatology 63 (5), 1118-1125, 2015 | 103 | 2015 |
| Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B GV Papatheodoridis, V Sypsa, GN Dalekos, C Yurdaydin, F Van Boemmel, ... Journal of hepatology 72 (6), 1088-1096, 2020 | 100 | 2020 |
| Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B GV Papatheodoridis, GN Dalekos, R Idilman, V Sypsa, F Van Boemmel, ... Journal of hepatology 73 (5), 1037-1045, 2020 | 85 | 2020 |
| Hepatitis B virus long‐term impact of antiviral therapy nucleot (s) ide analogues (NUC s) G Grossi, M Viganò, A Loglio, P Lampertico Liver International 37, 45-51, 2017 | 80 | 2017 |
| Treatment of hepatitis B: Is there still a role for interferon? M Viganò, G Grossi, A Loglio, P Lampertico Liver International 38, 79-83, 2018 | 74 | 2018 |
| Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients A Loglio, P Ferenci, SCU Renteria, CYL Tham, F van Bömmel, M Borghi, ... Journal of Hepatology 71 (4), 834-839, 2019 | 64 | 2019 |
| Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis A Loglio, P Ferenci, SCU Renteria, CYL Tham, C Scholtes, H Holzmann, ... Journal of hepatology 76 (2), 464-469, 2022 | 61 | 2022 |
| The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy A Loglio, M Iavarone, F Facchetti, D Di Paolo, R Perbellini, G Lunghi, ... Liver International 40 (8), 1987-1996, 2020 | 53 | 2020 |
| Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B G Acerbi, I Montali, GD Ferrigno, V Barili, S Schivazappa, A Alfieri, ... Journal of Hepatology 74 (4), 783-793, 2021 | 42 | 2021 |
| Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension E Degasperi, MP Anolli, SCU Renteria, D Sambarino, M Borghi, ... Journal of hepatology 77 (6), 1525-1531, 2022 | 41 | 2022 |
| Hepatitis delta virus acts as an immunogenic adjuvant in hepatitis B virus-infected hepatocytes CYL Tham, J Kah, AT Tan, T Volz, A Chia, K Giersch, Y Ladiges, A Loglio, ... Cell Reports Medicine 1 (4), 2020 | 31 | 2020 |
| Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance G Grossi, A Loglio, F Facchetti, M Borghi, R Soffredini, E Galmozzi, ... Journal of hepatology 68 (1), 195-198, 2018 | 29 | 2018 |
| A STAT 4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B R El Sharkawy, K Thabet, P Lampertico, S Petta, A Mangia, T Berg, ... Alimentary Pharmacology & Therapeutics 48 (5), 564-573, 2018 | 26 | 2018 |
| Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis MR Brunetto, I Carey, B Maasoumy, C Marcos‐Fosch, A Boonstra, ... Alimentary Pharmacology & Therapeutics 53 (6), 733-744, 2021 | 23 | 2021 |
| Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? M Viganò, A Loglio, G Grossi, P Lampertico Expert Review of Anti-Infective Therapy 16 (2), 153-161, 2018 | 20 | 2018 |
| Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study M Iavarone, G Tosetti, F Facchetti, M Topa, JM Er, SK Hang, D Licari, ... Digestive and Liver Disease 55 (2), 160-168, 2023 | 15 | 2023 |
| Genome-wide association study identifies genetic variants associated with early and sustained response to (pegylated) interferon in chronic hepatitis B patients: the GIANT-B study WP Brouwer, HLY Chan, P Lampertico, J Hou, P Tangkijvanich, ... Clinical Infectious Diseases 69 (11), 1969-1979, 2019 | 13 | 2019 |
